Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03

AUTHORS

Christine Blome, Matthias Augustin, Hidayet Metin, David Lohrberg

ABSTRACT

BACKGROUND: Since 2011, an early benefit assessment (EBA) of new drugs constricts free price setting in Germany. According to the Pharmaceutical Market Restructuring Act (AMNOG), pharmaceutical companies are obliged to demonstrate added benefit of new drugs over comparative treatment. Benefit is usually evaluated by the Institute for Quality and Efficiency in Health Care (IQWiG). The final appraisal is made by the Federal Joint Committee, Germany's highest-ranking decision body in the health sector, triggering drug prize negotiations between companies and statutory health insurance funds. One of four evaluation criteria is quality of life (QoL). QoL outcomes have, however, only rarely been pivotal in EBAs. OBJECTIVE: This study determined methodological requirements for QoL measurement and data presentation in the EBA. DESIGN: In a qualitative content analysis, documents of all EBAs completed by 2014 were searched for the term QoL. Relevant passages of all EBAs of 2011-2013 were independently extracted and reduced to key content by two researchers. Recurring patterns were identified and verified through comparison with EBAs of 2014. RESULTS: We identified a range of requirements regarding QoL assessment, analysis, presentation, and interpretation, which go beyond official regulations. Disease-specific questionnaires are preferred and have to be validated according to certain standards and in the respective patient group. Effects must exceed the minimal important difference, which in turn must be validated in compliance with specific requirements. Often, instruments were not accepted as QoL measures, sometimes inconsistently across EBAs. Another frequent reason for non-acceptance of QoL data was that more than 30 % of randomized patients could not be analyzed due to missing data. CONCLUSIONS: Non-compliance with methodological requirements for QoL evidence impairs chances for positive benefit evaluation. More... »

PAGES

181-193

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10198-016-0765-6

DOI

http://dx.doi.org/10.1007/s10198-016-0765-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004861521

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26837412


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Approval", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Industry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Germany", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Qualitative Research", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Medical Center Hamburg-Eppendorf", 
          "id": "https://www.grid.ac/institutes/grid.13648.38", 
          "name": [
            "German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Martinistra\u00dfe 52, 20246, Hamburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blome", 
        "givenName": "Christine", 
        "id": "sg:person.01164733634.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164733634.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Medical Center Hamburg-Eppendorf", 
          "id": "https://www.grid.ac/institutes/grid.13648.38", 
          "name": [
            "German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Martinistra\u00dfe 52, 20246, Hamburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Augustin", 
        "givenName": "Matthias", 
        "id": "sg:person.01216221061.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216221061.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag GmbH, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Metin", 
        "givenName": "Hidayet", 
        "id": "sg:person.01030063147.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030063147.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Medical Center Hamburg-Eppendorf", 
          "id": "https://www.grid.ac/institutes/grid.13648.38", 
          "name": [
            "German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Martinistra\u00dfe 52, 20246, Hamburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lohrberg", 
        "givenName": "David", 
        "id": "sg:person.01115074205.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115074205.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1524-4733.2010.00767.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003714640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.phf.2013.09.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008714996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.healthpol.2011.09.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009197798"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.healthpol.2012.12.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013435823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x14546377", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019711323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0272989x14546377", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019711323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-013-0495-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023978210", 
          "https://doi.org/10.1007/s10198-013-0495-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-013-0495-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023978210", 
          "https://doi.org/10.1007/s10198-013-0495-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.healthpol.2013.12.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026904666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.healthpol.2011.11.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029216518"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0168-8510(90)90421-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033898358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mlr.0b013e318268aaff", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044336632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mlr.0b013e318268aaff", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044336632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0090-4295(97)00459-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046835419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-540-46566-9_10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049710516", 
          "https://doi.org/10.1007/978-3-540-46566-9_10"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s0266462309090515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054887797"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s0266462312000530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054887889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0032-1323693", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057271859"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0033-1350528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057293861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.5.365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.3.570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082809601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057211"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03", 
    "datePublishedReg": "2017-03-01", 
    "description": "BACKGROUND: Since 2011, an early benefit assessment (EBA) of new drugs constricts free price setting in Germany. According to the Pharmaceutical Market Restructuring Act (AMNOG), pharmaceutical companies are obliged to demonstrate added benefit of new drugs over comparative treatment. Benefit is usually evaluated by the Institute for Quality and Efficiency in Health Care (IQWiG). The final appraisal is made by the Federal Joint Committee, Germany's highest-ranking decision body in the health sector, triggering drug prize negotiations between companies and statutory health insurance funds. One of four evaluation criteria is quality of life (QoL). QoL outcomes have, however, only rarely been pivotal in EBAs.\nOBJECTIVE: This study determined methodological requirements for QoL measurement and data presentation in the EBA.\nDESIGN: In a qualitative content analysis, documents of all EBAs completed by 2014 were searched for the term QoL. Relevant passages of all EBAs of 2011-2013 were independently extracted and reduced to key content by two researchers. Recurring patterns were identified and verified through comparison with EBAs of 2014.\nRESULTS: We identified a range of requirements regarding QoL assessment, analysis, presentation, and interpretation, which go beyond official regulations. Disease-specific questionnaires are preferred and have to be validated according to certain standards and in the respective patient group. Effects must exceed the minimal important difference, which in turn must be validated in compliance with specific requirements. Often, instruments were not accepted as QoL measures, sometimes inconsistently across EBAs. Another frequent reason for non-acceptance of QoL data was that more than 30\u00a0% of randomized patients could not be analyzed due to missing data.\nCONCLUSIONS: Non-compliance with methodological requirements for QoL evidence impairs chances for positive benefit evaluation.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10198-016-0765-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297512", 
        "issn": [
          "1439-3972", 
          "1439-6637"
        ], 
        "name": "The European Journal of Health Economics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data", 
    "pagination": "181-193", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "172a9cc4193f619517cc2fe6a22aae1e555f435aefe0d204f401a7272fed4db9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26837412"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101134867"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10198-016-0765-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004861521"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10198-016-0765-6", 
      "https://app.dimensions.ai/details/publication/pub.1004861521"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000479.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10198-016-0765-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0765-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0765-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0765-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10198-016-0765-6'


 

This table displays all metadata directly associated to this object as RDF triples.

200 TRIPLES      21 PREDICATES      60 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10198-016-0765-6 schema:about N0de2a4fd9aaa44fc9a22634ced7e83e8
2 N10f2bad623a74da1a37f6038655bffcf
3 N13677f839b0849418615f45714626613
4 N191fb46072024855b3df71a9bdd5b061
5 N3638f2419e43487da81a678e6cbfda54
6 N7e26956456374296a589226e72d1e95f
7 N93fbbfabf6524ee5af79f7ddf13e704d
8 Naca8de2df774438a829fbde923824aa2
9 Ne34eb8f587d4485da604bd84aaf7d924
10 Ne7ef226ee19a4ecca45fef45f9b830a7
11 Nf81692c40f9d492282b1735f473447b7
12 Nfffb85b8f22a41468b5225ef4fd8059b
13 anzsrc-for:14
14 anzsrc-for:1402
15 schema:author Nac7616964f9046d2b7efeba40d018fa0
16 schema:citation sg:pub.10.1007/978-3-540-46566-9_10
17 sg:pub.10.1007/s10198-013-0495-y
18 https://doi.org/10.1016/0168-8510(90)90421-9
19 https://doi.org/10.1016/j.healthpol.2011.09.008
20 https://doi.org/10.1016/j.healthpol.2011.11.006
21 https://doi.org/10.1016/j.healthpol.2012.12.005
22 https://doi.org/10.1016/j.healthpol.2013.12.008
23 https://doi.org/10.1016/j.phf.2013.09.011
24 https://doi.org/10.1016/s0090-4295(97)00459-7
25 https://doi.org/10.1017/s0266462309090515
26 https://doi.org/10.1017/s0266462312000530
27 https://doi.org/10.1055/s-0032-1323693
28 https://doi.org/10.1055/s-0033-1350528
29 https://doi.org/10.1093/jnci/85.5.365
30 https://doi.org/10.1097/mlr.0b013e318268aaff
31 https://doi.org/10.1111/j.1524-4733.2010.00767.x
32 https://doi.org/10.1177/0272989x14546377
33 https://doi.org/10.1200/jco.1993.11.3.570
34 https://doi.org/10.1200/jco.1997.15.3.974
35 schema:datePublished 2017-03
36 schema:datePublishedReg 2017-03-01
37 schema:description BACKGROUND: Since 2011, an early benefit assessment (EBA) of new drugs constricts free price setting in Germany. According to the Pharmaceutical Market Restructuring Act (AMNOG), pharmaceutical companies are obliged to demonstrate added benefit of new drugs over comparative treatment. Benefit is usually evaluated by the Institute for Quality and Efficiency in Health Care (IQWiG). The final appraisal is made by the Federal Joint Committee, Germany's highest-ranking decision body in the health sector, triggering drug prize negotiations between companies and statutory health insurance funds. One of four evaluation criteria is quality of life (QoL). QoL outcomes have, however, only rarely been pivotal in EBAs. OBJECTIVE: This study determined methodological requirements for QoL measurement and data presentation in the EBA. DESIGN: In a qualitative content analysis, documents of all EBAs completed by 2014 were searched for the term QoL. Relevant passages of all EBAs of 2011-2013 were independently extracted and reduced to key content by two researchers. Recurring patterns were identified and verified through comparison with EBAs of 2014. RESULTS: We identified a range of requirements regarding QoL assessment, analysis, presentation, and interpretation, which go beyond official regulations. Disease-specific questionnaires are preferred and have to be validated according to certain standards and in the respective patient group. Effects must exceed the minimal important difference, which in turn must be validated in compliance with specific requirements. Often, instruments were not accepted as QoL measures, sometimes inconsistently across EBAs. Another frequent reason for non-acceptance of QoL data was that more than 30 % of randomized patients could not be analyzed due to missing data. CONCLUSIONS: Non-compliance with methodological requirements for QoL evidence impairs chances for positive benefit evaluation.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf N22518b0e826f49c39817943d690b2fda
42 N9a10b3f38f43433d9102a4dbd96a154a
43 sg:journal.1297512
44 schema:name Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
45 schema:pagination 181-193
46 schema:productId N2954b142978c4b98bf347c822a716278
47 N754ee0d406de45cea33e93b58b0453d0
48 N7afc15af929343eb9e9dde14ffed4ce0
49 N8f12a38996a4443cb91851470be130a5
50 Na29402d60be44f1c8524dd0ce90fee3f
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004861521
52 https://doi.org/10.1007/s10198-016-0765-6
53 schema:sdDatePublished 2019-04-10T19:50
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher N9030d685c75243ce9429bc77962b0b75
56 schema:url http://link.springer.com/10.1007/s10198-016-0765-6
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N0de2a4fd9aaa44fc9a22634ced7e83e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Cost-Benefit Analysis
62 rdf:type schema:DefinedTerm
63 N10f2bad623a74da1a37f6038655bffcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Humans
65 rdf:type schema:DefinedTerm
66 N13677f839b0849418615f45714626613 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Bias
68 rdf:type schema:DefinedTerm
69 N191fb46072024855b3df71a9bdd5b061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Costs and Cost Analysis
71 rdf:type schema:DefinedTerm
72 N22518b0e826f49c39817943d690b2fda schema:volumeNumber 18
73 rdf:type schema:PublicationVolume
74 N26bb0977201c40ad887df6617e6b261d rdf:first sg:person.01115074205.23
75 rdf:rest rdf:nil
76 N2954b142978c4b98bf347c822a716278 schema:name nlm_unique_id
77 schema:value 101134867
78 rdf:type schema:PropertyValue
79 N3638f2419e43487da81a678e6cbfda54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Reproducibility of Results
81 rdf:type schema:DefinedTerm
82 N6302bd1a30b946909794104317fdb505 rdf:first sg:person.01030063147.68
83 rdf:rest N26bb0977201c40ad887df6617e6b261d
84 N754ee0d406de45cea33e93b58b0453d0 schema:name pubmed_id
85 schema:value 26837412
86 rdf:type schema:PropertyValue
87 N7afc15af929343eb9e9dde14ffed4ce0 schema:name dimensions_id
88 schema:value pub.1004861521
89 rdf:type schema:PropertyValue
90 N7e26956456374296a589226e72d1e95f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Germany
92 rdf:type schema:DefinedTerm
93 N8f12a38996a4443cb91851470be130a5 schema:name readcube_id
94 schema:value 172a9cc4193f619517cc2fe6a22aae1e555f435aefe0d204f401a7272fed4db9
95 rdf:type schema:PropertyValue
96 N9030d685c75243ce9429bc77962b0b75 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N93fbbfabf6524ee5af79f7ddf13e704d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Drug Approval
100 rdf:type schema:DefinedTerm
101 N9a10b3f38f43433d9102a4dbd96a154a schema:issueNumber 2
102 rdf:type schema:PublicationIssue
103 N9e54608a892b49419eacaff7df9a53c7 rdf:first sg:person.01216221061.07
104 rdf:rest N6302bd1a30b946909794104317fdb505
105 Na29402d60be44f1c8524dd0ce90fee3f schema:name doi
106 schema:value 10.1007/s10198-016-0765-6
107 rdf:type schema:PropertyValue
108 Nac7616964f9046d2b7efeba40d018fa0 rdf:first sg:person.01164733634.96
109 rdf:rest N9e54608a892b49419eacaff7df9a53c7
110 Naca8de2df774438a829fbde923824aa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Surveys and Questionnaires
112 rdf:type schema:DefinedTerm
113 Ne34eb8f587d4485da604bd84aaf7d924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Qualitative Research
115 rdf:type schema:DefinedTerm
116 Ne7ef226ee19a4ecca45fef45f9b830a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Drug Industry
118 rdf:type schema:DefinedTerm
119 Nf81692c40f9d492282b1735f473447b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Quality of Life
121 rdf:type schema:DefinedTerm
122 Nfffb85b8f22a41468b5225ef4fd8059b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Research Design
124 rdf:type schema:DefinedTerm
125 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
126 schema:name Economics
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
129 schema:name Applied Economics
130 rdf:type schema:DefinedTerm
131 sg:journal.1297512 schema:issn 1439-3972
132 1439-6637
133 schema:name The European Journal of Health Economics
134 rdf:type schema:Periodical
135 sg:person.01030063147.68 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
136 schema:familyName Metin
137 schema:givenName Hidayet
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030063147.68
139 rdf:type schema:Person
140 sg:person.01115074205.23 schema:affiliation https://www.grid.ac/institutes/grid.13648.38
141 schema:familyName Lohrberg
142 schema:givenName David
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115074205.23
144 rdf:type schema:Person
145 sg:person.01164733634.96 schema:affiliation https://www.grid.ac/institutes/grid.13648.38
146 schema:familyName Blome
147 schema:givenName Christine
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164733634.96
149 rdf:type schema:Person
150 sg:person.01216221061.07 schema:affiliation https://www.grid.ac/institutes/grid.13648.38
151 schema:familyName Augustin
152 schema:givenName Matthias
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216221061.07
154 rdf:type schema:Person
155 sg:pub.10.1007/978-3-540-46566-9_10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049710516
156 https://doi.org/10.1007/978-3-540-46566-9_10
157 rdf:type schema:CreativeWork
158 sg:pub.10.1007/s10198-013-0495-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1023978210
159 https://doi.org/10.1007/s10198-013-0495-y
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/0168-8510(90)90421-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033898358
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1016/j.healthpol.2011.09.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009197798
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1016/j.healthpol.2011.11.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029216518
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1016/j.healthpol.2012.12.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013435823
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/j.healthpol.2013.12.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026904666
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1016/j.phf.2013.09.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008714996
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1016/s0090-4295(97)00459-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046835419
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1017/s0266462309090515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054887797
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1017/s0266462312000530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054887889
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1055/s-0032-1323693 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057271859
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1055/s-0033-1350528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057293861
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1093/jnci/85.5.365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818446
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1097/mlr.0b013e318268aaff schema:sameAs https://app.dimensions.ai/details/publication/pub.1044336632
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1111/j.1524-4733.2010.00767.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003714640
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1177/0272989x14546377 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019711323
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1200/jco.1993.11.3.570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082809601
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1200/jco.1997.15.3.974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057211
194 rdf:type schema:CreativeWork
195 https://www.grid.ac/institutes/grid.13648.38 schema:alternateName University Medical Center Hamburg-Eppendorf
196 schema:name German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
197 rdf:type schema:Organization
198 https://www.grid.ac/institutes/grid.497524.9 schema:alternateName Janssen (Germany)
199 schema:name Janssen-Cilag GmbH, Neuss, Germany
200 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...